The artist formerly known as G-Therapeutics has justified the large – by 2016 standards – series A round it raised two and a half years ago by posting extraordinary results from early human studies of its spinal cord stimulation system. The technology developed by the company, which now goes by the name GTX Medical, helped three patients with spinal cord injury, who would not usually be expected to see a change in their status, to walk with support following intermittent epidural electrical stimulation of the spinal cord. Even more impressively, two of these patients maintained their walking ability after the stimulator was turned off, suggesting that new nerve connections might have been formed. GTX now has to raise rather more cash than its €26m series A to fund further clinical trials. Speaking with Vantage in 2016 GTX’s chief executive, Sjaak Deckers, said the company hoped to have a regulatory submission ready in late 2019 ($29m for prototype-stage G-Therapeutics, April 21, 2016). It is not clear whether the group can stick to this ambitious schedule, and how it will pay for the development.